Potassium Phosphate Injection Shortage

• • Potassium Phosphate injection, CMP Pharma, 3 mmol/mL, 15 mL vial, 10 count, NDC 46287-0024-10 - discontinued
  • Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01

• • American Regent has potassium phosphate injection available.
  • Amneal has potassium phosphate injection available.
  • CMP Pharma discontinued potassium phosphate injection in 2024.
  • Fresenius Kabi did not provide a reason for the shortage.
  • Pfizer has potassium phosphate injection on shortage due to manufacturing delays.
  • Somerset has potassium phosphate injection available.

• • Potassium Phosphate injection, American Regent, 3 mmol/mL, 15 mL vial, 25 count, NDC 00517-2102-25
  • Potassium Phosphate injection, American Regent, 3 mmol/mL, 5 mL vial, 25 count, NDC 00517-2051-25
  • Potassium Phosphate injection, American Regent, 3 mmol/mL, 50 mL vial, 25 count, NDC 00517-2505-25
  • Potassium Phosphate injection, Amneal, 3 mmol/mL, 15 mL vial, 30 count, NDC 80830-1691-02
  • Potassium Phosphate injection, Amneal, 3 mmol/mL, 5 mL vial, 30 count, NDC 80830-1693-03
  • Potassium Phosphate injection, Amneal, 3 mmol/mL, 50 mL vial, 15 count, NDC 80830-1692-02
  • Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 15 mL vial, 25 count, NDC 70069-0747-25
  • Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 5 mL vial, 25 count, NDC 70069-0746-25
  • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 65219-0054-29
  • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 65219-0052-29
  • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 65219-0056-29
  • Potassium Phosphate injection, Amneal, 15 mmoL/250 mL, premixed bag, 24 count, NDC 70121-1722-09

Estimated Resupply Dates

• • Pfizer has potassium phosphate 3 mmol/mL 15 mL vials on back order and the company cannot estimate a release date.

Safety

• • FDA continues to be concerned about the risk of aluminum toxicity associated with unapproved potassium phosphate products in pediatric patients. Pfizer (Hospira) has agreed to stop distributing their unapproved product within 90 days of August 1, 2024. There are generic products that have been approved since February 2023 that have acceptable aluminum levels. More information can be found at: https://www.fda.gov/drugs/drug-safety-and-availability/infants-risk-aluminum-toxicity-unapproved-potassium-phosphates-drug-product